Press release
Renal Cell Carcinoma Pipeline Appears Robust With 30+ Companies Actively Working in the Therapeutics Segment | DelveInsight
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Renal Cell Carcinoma Treatment Landscape. Click here to read more @ Renal Cell Carcinoma Pipeline Outlook [https://www.delveinsight.com/sample-request/renal-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Renal Cell Carcinoma Pipeline Report
* In May 2025, Merck Sharp & Dohme LLC announced a study is to evaluate the efficacy and safety of belzutifan monotherapy and belzutifan plus palbociclib combination therapy in participants with advanced clear-cell renal cell carcinoma (ccRCC) who experienced disease progression on or after receiving prior therapy. Part 1 will establish the safety of belzutifan plus palbociclib and determine a recommended dosage of palbociclib for the combination therapy by ascending dose escalation. Part 2 will evaluate the efficacy and safety of belzutifan plus palbociclib at the dosage level determined in Part 1.
* In May 2025, Karie Runcie announced a Phase 2 study will include men and women greater than or equal to 18 with confirmed renal cell carcinoma who have progressed on adjuvant anti-PD-1/PD-L1 therapy, the current standard of care. Subjects will be randomized to Arm A or Arm B. Study treatment will be given in 28-day (4 week) cycles. Arm A treatment will consist of XL092 alone and will be taken once daily continuously (Day 1-Day 28). Arm B treatment will consist of XL092 plus nivolumab. XL092 will be taken once daily continuously (Day 1-Day 28) and nivolumab will be administered every 4 weeks (Day 1). Treatment will continue until progression by RECIST 1.1, toxicity, or other reasons as appropriate.
* DelveInsight's Renal Cell Carcinoma Pipeline report depicts a robust space with 30+ active players working to develop 30+ pipeline therapies for Renal Cell Carcinoma treatment.
* The leading Renal Cell Carcinoma Companies such as AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals , and others.
* Promising Renal Cell Carcinoma Therapies such as PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.
Discover groundbreaking developments in Renal Cell Carcinoma therapies! Gain in-depth knowledge of key Renal Cell Carcinoma clinical trials, emerging drugs, and market opportunities @ Renal Cell Carcinoma Clinical Trials Assessment [https://www.delveinsight.com/sample-request/renal-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Renal Cell Carcinoma Emerging Drugs Profile
* CM082: Betta Pharmaceuticals
CM082 series have the similar skeletal structures to Icotinib Hydrochloride, as the multi-target RTK (receptor tyrosine kinase) inhibitor, mainly targeting at VEGFR and PDGFR. The drug is being evaluated in phase III stage of development for the treatment of Renal Cell Carcinoma.
* TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
TQB 2450 (formerly APL 502 and CBT 502) is a humanised immunoglobulin G1 (IgG1) monoclonal antibody targeting the programmed cell death-1 ligand-1. Phase III clinical trials are being evaluated by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. for TQB 2450 for the treatment of renal cell carcinoma.
* IPI-549: Infinity Pharmaceuticals
IPI-549 is an oral immuno-oncology candidate which has been designed to preferentially inhibit PI3K-gamma. The drug is being studied in phase II stage of development for the treatment of renal cell carcinoma.
* CMN-001: ColImmune
Dendritic cells have been used by colimmune for the treatment of renal failure. CMN001 is a dendritic cell vaccine for renal cell carcinoma. The drug is being evaluated in phase II stage of development for the treatment of renal cell carcinoma.
The Renal Cell Carcinoma Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Renal Cell Carcinoma with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Renal Cell Carcinoma Treatment.
* Renal Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Renal Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Renal Cell Carcinoma market.
Stay informed about the Renal Cell Carcinoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Renal Cell Carcinoma Unmet Needs [https://www.delveinsight.com/sample-request/renal-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Renal Cell Carcinoma Companies
AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.
Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Subcutaneous
* Intravenous
* Intramuscular
* Molecule Type
Renal Cell Carcinoma Products have been categorized under various Molecule types such as
* Bispecific Antibody
* Peptides
* Small molecule
* Gene therapy
* Product Type
Transform your understanding of the Renal Cell Carcinoma Pipeline! See the latest progress in drug development and clinical research @ Renal Cell Carcinoma Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/renal-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Renal Cell Carcinoma Pipeline Report
* Coverage- Global
* Renal Cell Carcinoma Companies- AstraZeneca, Infinity Pharmaceuticals, Ipsen, Novartis, Aveao pharmaceuticals, Merck Sharp & Dohme Corp., Pfizer, Bayer Healthcare, Incyte Corporation, GlaxoSmithKline, Bristol-Myers Squibb, Hoffman La Roche, Amgen, ColImmune, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Betta Pharmaceuticals, Regeneron Pharmaceuticals, Cemiplimab, Aravivie Inc, X4 pharmaceuticals, and others.
* Renal Cell Carcinoma Therapies- PRO1160, Cabozantinib, CTX131, Ipilimumab, Nivolumab, Zanzalintinib, AB521, and others.
* Renal Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Renal Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Oncology Research-Access the Full Renal Cell Carcinoma Pipeline Analysis Today! @ Renal Cell Carcinoma Drugs and Companies [https://www.delveinsight.com/sample-request/renal-cell-carcinoma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Renal Cell Carcinoma Executive Summary
* Renal Cell Carcinoma: Overview
* Renal Cell Carcinoma Pipeline Therapeutics
* Renal Cell Carcinoma Therapeutic Assessment
* Renal Cell Carcinoma - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Renal Cell Carcinoma Collaboration Deals
* Late Stage Products (Phase III)
* TQB 2450: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* IPI-549: Infinity Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AVB-S6-500: Aravive Inc.
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug Name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Renal Cell Carcinoma Key Companies
* Renal Cell Carcinoma Key Products
* Renal Cell Carcinoma - Unmet Needs
* Renal Cell Carcinoma - Market Drivers and Barriers
* Renal Cell Carcinoma - Future Perspectives and Conclusion
* Renal Cell Carcinoma Analyst Views
* Renal Cell Carcinoma Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=renal-cell-carcinoma-pipeline-appears-robust-with-30-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/renal-cell-carcinoma-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Renal Cell Carcinoma Pipeline Appears Robust With 30+ Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4004394 • Views: …
More Releases from ABNewswire
Is Couples Therapy Right? Signs It's Time to See a Counsellor in Birmingham
Relationships can be both fulfilling and challenging. No matter how strong a couple may seem on the outside, it's natural to face hurdles along the way. Miscommunication, stress, life changes, or unresolved issues can create distance between partners. While every couple goes through ups and downs, knowing when to seek professional support can make all the difference. If you've ever found yourself searching for "couples therapy near me" or wondering…
Rialto-Based Get it from Bo Pioneers Collaborative E-Commerce Model Supporting M …
Get it from Bo revolutionizes online retail through strategic manufacturer partnerships that deliver quality products at reasonable prices. The California-based platform, established in 2024, creates sustainable business relationships while expanding inventory daily to serve diverse consumer needs.
Get it from Bo is establishing new standards in the e-commerce industry through its innovative collaborative approach that prioritizes sustainable partnerships with manufacturers and brands while delivering exceptional value to consumers. The Rialto, California-based…
Daily Vibe Launches Comprehensive Fitness Products Store for Diverse Consumer Ma …
New fitness retailer Daily Vibe enters the market with targeted product selections designed to support active lifestyles across multiple demographics. The startup focuses on serving fitness enthusiasts, health-conscious consumers, and older adults seeking quality fitness products.
Founded by Ja'von L. Watson and Joyleena S. Watson, AGAIT International is a fast-growing Atlanta-based tech company dedicated to solving social and economic challenges through creative business and digital solutions. The company develops and manages…
Prolift Handling Brings Advanced pewag Lifting Technology to Ireland
Prolift Handling launches pewag levo Balancer and levo Compensator in Ireland - two advanced lifting solutions that improve safety and precision in heavy lifting operations through remote-controlled positioning and automatic load balancing.
Dublin, Ireland - Sep 30, 2025 - Prolift Handling, Ireland's exclusive pewag partner, today launched two advanced lifting solutions designed to tackle the industry's most challenging safety and precision requirements: the pewag levo Balancer and pewag levo Compensator.
The pewag…
More Releases for Renal
Advancements in Renal Dialysis Equipment Trend: A Crucial Influence on the Renal …
What market dynamics are playing a key role in accelerating the growth of the renal dialysis equipment market?
The escalating incidence of chronic kidney disease is projected to boost the expansion of the renal dialysis equipment market. Chronic kidney disease, a term that describes the slow and progressive decline of kidney function, can ultimately result in kidney failure and other severe health conditions. This disease is linked with several risk factors…
Renal Osteodystrophy Market: An In-Depth Analysis
The Renal Osteodystrophy Market was valued at approximately USD 2.4 billion in 2023 and is projected to reach around USD 7.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2032.
Renal Osteodystrophy Market Overview
The Renal Osteodystrophy Market is experiencing significant growth, driven by the increasing prevalence of chronic kidney disease (CKD) and the associated bone disorders. Advancements in diagnostic techniques have enhanced early…
Shaping the Renal Dialysis Equipment Market in 2025: Advancements in Renal Dialy …
How Big Is the Renal Dialysis Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent years, the renal dialysis equipment market has seen robust growth. It's projected to increase from $19.52 billion in 2024 to $20.92 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.2%. Factors contributing to growth in the historic period include comprehensive training and support programs, substantial research and development…
Transforming the Veterinary Renal Disease Market in 2025: Increasing Pet Ownersh …
"What Is the Expected Size and Growth Rate of the Veterinary Renal Disease Market?
The market size for veterinary kidney diseases has seen profound growth recently. It is set to expand from $15.5 billion in 2024 to $16.63 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. Several factors contributed to this growth during the historical period, including heightened initiatives to increase disease awareness, a shift in…
Renal Cancer Pipeline Outlook Report 2024
DelveInsight's, "Renal Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Renal Biomarker Market to register a CAGR of 7.0% by 2026: Rising Prevalence of …
Future Market Insights delivers key insights on the global renal biomarker market in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” In terms of revenue, the global renal biomarker market is projected to register a healthy CAGR of 7.0% over the forecast period. In this report, Future Market Insights throws light on the various factors and trends impacting market growth over the forecast period…
